SG Americas Securities LLC Buys 5,600 Shares of Bio-Rad Laboratories, Inc. $BIO

SG Americas Securities LLC lifted its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 688.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,414 shares of the medical research company’s stock after buying an additional 5,600 shares during the quarter. SG Americas Securities LLC’s holdings in Bio-Rad Laboratories were worth $1,798,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of BIO. Royal Bank of Canada lifted its stake in Bio-Rad Laboratories by 25.2% in the 1st quarter. Royal Bank of Canada now owns 30,310 shares of the medical research company’s stock worth $7,382,000 after purchasing an additional 6,100 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Bio-Rad Laboratories by 45.6% in the first quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company’s stock worth $25,575,000 after purchasing an additional 32,874 shares during the last quarter. Empowered Funds LLC lifted its position in shares of Bio-Rad Laboratories by 14.8% in the first quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company’s stock worth $377,000 after buying an additional 199 shares in the last quarter. Jane Street Group LLC boosted its stake in Bio-Rad Laboratories by 95.3% during the first quarter. Jane Street Group LLC now owns 37,383 shares of the medical research company’s stock valued at $9,105,000 after buying an additional 18,239 shares during the last quarter. Finally, Inspire Investing LLC boosted its stake in Bio-Rad Laboratories by 62.4% during the first quarter. Inspire Investing LLC now owns 1,281 shares of the medical research company’s stock valued at $312,000 after buying an additional 492 shares during the last quarter. 65.24% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, EVP James Barry sold 700 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $306.18, for a total transaction of $214,326.00. Following the completion of the transaction, the executive vice president owned 510 shares in the company, valued at $156,151.80. The trade was a 57.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 17.06% of the stock is currently owned by insiders.

Bio-Rad Laboratories Stock Down 1.3%

NYSE BIO opened at $318.12 on Thursday. The company has a quick ratio of 3.94, a current ratio of 5.44 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 52 week low of $211.43 and a 52 week high of $373.69. The firm has a market capitalization of $8.58 billion, a price-to-earnings ratio of -13.09 and a beta of 1.18. The company has a fifty day moving average of $312.67 and a two-hundred day moving average of $293.70.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Wednesday, October 29th. The medical research company reported $2.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.30 by ($0.04). The firm had revenue of $653.00 million during the quarter, compared to the consensus estimate of $651.30 million. Bio-Rad Laboratories had a positive return on equity of 4.19% and a negative net margin of 26.43%.Bio-Rad Laboratories’s revenue was up .5% compared to the same quarter last year. During the same quarter last year, the business posted $2.01 EPS. On average, analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Wall Street Analyst Weigh In

BIO has been the topic of several recent research reports. Wall Street Zen raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Citigroup boosted their price target on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Monday, December 29th. Finally, Wells Fargo & Company lifted their price objective on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Bio-Rad Laboratories has a consensus rating of “Hold” and a consensus target price of $358.50.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.